BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17714059)

  • 1. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation.
    Ng FL; Holt DW; MacPhee IA
    Expert Opin Pharmacother; 2007 Sep; 8(13):2045-58. PubMed ID: 17714059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.
    Ekbal NJ; Holt DW; Macphee IA
    Pharmacogenomics; 2008 May; 9(5):585-96. PubMed ID: 18466104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?
    MacPhee IA; Fredericks S; Holt DW
    Expert Opin Pharmacother; 2005 Dec; 6(15):2593-605. PubMed ID: 16316299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.
    Cattaneo D; Baldelli S; Perico N
    Am J Transplant; 2008 Jul; 8(7):1374-83. PubMed ID: 18510642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs.
    Kurzawski M; Droździk M
    Pharmacogenomics; 2013 Jul; 14(9):1099-118. PubMed ID: 23837483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practicability of pharmacogenetics in transplantation medicine.
    van Gelder T; van Schaik RH; Hesselink DA
    Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration.
    Fredericks S; Holt DW; MacPhee IA
    Am J Pharmacogenomics; 2003; 3(5):291-301. PubMed ID: 14575518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms influencing therapy and susceptibility to rejection in organ allograft recipients.
    Poli F; Piccolo G; Scalamogna M
    BioDrugs; 2002; 16(1):11-7. PubMed ID: 11908998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.
    Picard N; Bergan S; Marquet P; van Gelder T; Wallemacq P; Hesselink DA; Haufroid V
    Ther Drug Monit; 2016 Apr; 38 Suppl 1():S57-69. PubMed ID: 26469711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
    Ware N; MacPhee IA
    Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives.
    Anglicheau D; Legendre C; Thervet E
    Transplantation; 2004 Aug; 78(3):311-5. PubMed ID: 15316356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine.
    Oscarson M
    Clin Chem Lab Med; 2003 Apr; 41(4):573-80. PubMed ID: 12747605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of mycophenolate mofetil: a promising different approach to tailoring immunosuppression?
    Betonico GN; Abudd-Filho M; Goloni-Bertollo EM; Pavarino-Bertelli E
    J Nephrol; 2008; 21(4):503-9. PubMed ID: 18651539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics in drug regulation: promise, potential and pitfalls.
    Shah RR
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1617-38. PubMed ID: 16096112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
    Thervet E; Legendre C; Beaune P; Anglicheau D
    Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genes and beans: pharmacogenomics of renal transplant.
    Murray B; Hawes E; Lee RA; Watson R; Roederer MW
    Pharmacogenomics; 2013 May; 14(7):783-98. PubMed ID: 23651025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
    Coto E; Tavira B
    Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
    Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
    Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?
    Burckart GJ; Liu XI
    Ther Drug Monit; 2006 Feb; 28(1):23-30. PubMed ID: 16418689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.